PhenixFIN Q4 2022: NII $1.9M, NAV $57.49/shr, new $50M credit facility

PhenixFIN Corp

Q4 total investment income $5.1M, net investment income $1.9M.
NAV $120.8M ($57.49/shr) vs $57.08/shr a year ago; portfolio fair value $193.0M.
Secured 3-yr $50M credit facility (SOFR+2.90%); will redeem $22.5M 6.125% notes due 2023.
Repurchased 16.5% of shares outstanding in FY2022; weighted avg yield to maturity 10.85%.
Net realized loss $10.3M on sale of Path Medical; net unrealized loss $3.7M from market volatility.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PhenixFIN Corp reported fiscal fourth quarter of 2022 results: revenue $5.1 million, net income $1.9 million.

Period: fiscal fourth quarter of 2022
Revenue: $5.1 million
Net income: $1.9 million
Result: reported results

Exact text from the filing

traded business development company, today announced its financial results for the fiscal fourth quarter of 2022. Highlights ● Fourth quarter total investment income was $5.1 million; net investment income of $1.9 million ● Net asset value (NAV) of $120.8 million, or $57.49 per share as of September 30, 2022, vs. $57.08 per share as of September 30, 2021 ●

View on SEC.gov

Browse all earnings releases →

PhenixFIN Corp filing history →

Source: SEC EDGAR

accession 0001213900-22-080280

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.